Please provide your email address to receive an email when new articles are posted on . Intravitreal steroids have been widely used in the treatment of various ocular pathologies including macular ...
A sustained-release dexamethasone device implanted during pars plana vitrectomy may be effective in pre-emptively reducing macular edema in patients with various underlying ocular diseases at risk for ...
The US Food and Drug Administration has approved Allergan's Ozurdex (dexamethasone intravitreal implant) 0.7 mg for use in adult patients with diabetic macular edema who have had an artificial lens ...
IRVINE, Calif.--(BUSINESS WIRE)--Allergan, Inc., (NYSE: AGN) announced today that the U.S. Food and Drug Administration (FDA) has approved OZURDEX® (dexamethasone intravitreal implant) 0.7 mg, a ...
To evaluate the morphological and functional changes following intravitreal Ozurdex (dexamethasone implant) injections in patients with macular oedema (MO) secondary to retinal vascular diseases. The ...
Sixty-four eyes were prospectively investigated. Group 1 (22 central retinal vein occlusion (CRVO) and 16 branch retinal vein occlusion (BRVO)) was treated with Ozurdex alone, and group 2 (14 CRVO and ...
Allergan’s eye drug Ozurdex has been approved in the EU to treat a sight-threatening condition that affects people with diabetes. The European Commission granted marketing authorisation to Ozurdex, an ...
OZURDEX (dexamethasone) intravitreal implant Allergan announced that the Food and Drug Administration (FDA) has approved Ozurdex (dexamethasone intravitreal implant) for the treatment of diabetic ...
The Indian rupee is expected to face continued pressure in the coming week, and traders will take cues from how forcefully the Reserve Bank of India defends the currency near its all-time low.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results